DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/s5xb5x/pancreatitis) has announced the addition of Global Markets Direct's new report "Pancreatitis - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Pancreatitis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pancreatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatitis. Pancreatitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
- A snapshot of the global therapeutic scenario for Pancreatitis.
- A review of the Pancreatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pancreatitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Key Topics Covered:
- List of Tables
- List of Figures
- Report Coverage
- Pancreatitis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Pancreatitis
- Pancreatitis Therapeutics under Development by Companies
- Pancreatitis Therapeutics under Investigation by Universities/Institutes
- Mid Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Pancreatitis Therapeutics - Products under Development by Companies
- Pancreatitis Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Pancreatitis Therapeutics Development
- Pancreatitis - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Pancreatitis Therapeutics - Dormant Products
- Pancreatitis - Product Development Milestones
- Featured News & Press Releases
- Jun 29, 2011: Amsterdam Molecular Therapeutics's Glybera Significantly Reduces Risk Of Pancreatitis In LPLD Patients
- Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan
- Secondary Research
- Primary Research
- Expert Panel Validation
For more information visit http://www.researchandmarkets.com/research/s5xb5x/pancreatitis
Source: Global Markets Direct